Getinge's subsidiary Maquet Cardiovascular receives adverse jury trial verdict in patent infringement dispute with Abiomed in the U.S.
IoMT Wearable Devices Patent Landscape Report and Forecasts, 2017-2023 & 2024-2032 Featuring Veniam, Advanced Neuromodulation Systems, Bionet Sonar, and Abiomed
US FDA classifies recall of Abiomed's blood pumps as most serious
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
Warren Buffett Loves These Stocks. Should You Buy Them Before 2023?
Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, OPNT, BNFT, ABMD
First Patients in the World Treated with Impella RP Flex with SmartAssist
Eleven Stocks Turned $10,000 To $261,421 In 11 Months
Johnson & Johnson Could Level Up With Its $16.8 Billion Purchase of Abiomed
Is Johnson & Johnson's Purchase of Abiomed Good for Investors?
Beat the Dow Jones With This Unstoppable Dividend Stock
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating ABIOMED, Inc. Buyout
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATCO, ABMD, BNFT
ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD
SHAREHOLDER ALERT: Weiss Law Investigates Abiomed, Inc.
Why Abiomed Stock Skyrocketed Today
Abiomed Shares Pop 50% on Johnson & Johnson Buyout
Abiomed, Inc. (ABMD) Q2 2023 Earnings Call Transcript
J&J Agrees to Buy Heart-Device Maker Abiomed for $16.6 Billion
Abiomed (ABMD) Q2 Earnings Top Estimates, Margins Down
This medical devices stock opened 50% up on Tuesday: here's why
Shareholder Alert: Ademi LLP investigates whether ABIOMED, Inc. has obtained a Fair Price in its transaction with Johnson & Johnson
Abiomed (ABMD) Beats Q2 Earnings Estimates
J&J to buy Abiomed in $16.6B deal to boost cardiovascular business
ABMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ABIOMED, Inc. Is Fair to Shareholders
Abiomed Stock Surges on Johnson & Johnson Takeover
Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
Abiomed stock rockets after J&J buyout deal valued at $16.6 billion
Johnson & Johnson to Acquire Abiomed
Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure
Is Abiomed (ABMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare
MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson
Abiomed's (ABMD) Latest Impella Offering Approved by the FDA
Why Abiomed (ABMD) Could Beat Earnings Estimates Again
Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure
U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath
Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support
Abiomed (ABMD) is an Incredible Growth Stock: 3 Reasons Why
Abiomed: Correction Offers Good Buying Opportunity
Abiomed (ABMD) Posts Impellas Positive Study Results in Japan
Abiomed's (ABMD) Impella-Related Research Gets FDA Clearance
Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery